Bipolar Depression Presentation
Patient presents in a depressive episode within bipolar disorder.
- Depressive: Episode Polarity (placeholder metric)
- ≥1: Prior Manic Episodes (placeholder metric)
- ~40%: Misdiagnosis Rate (placeholder metric)
- MDQ: Screening Tool (placeholder metric)
Clinical picture
Low mood, anergia and anhedonia dominate the presentation.
Diagnostic caution
Ruling out unipolar depression guides safer drug choice.
Placeholder: unrecognized bipolarity raises switch risk later.
Baseline severity
Severity score anchors the mood dial before treatment.
Quetiapine / Lurasidone / Lamotrigine
Approved agents move mood toward euthymia without antidepressant risk.
- 300 mg: Quetiapine XR (placeholder dose)
- 20–120 mg: Lurasidone (placeholder dose)
- 200 mg: Lamotrigine (placeholder target)
- Low: Switch Risk (placeholder metric)
Mechanism
Each agent stabilizes mood via distinct receptor pathways.
Titration
Slow titration limits sedation and metabolic side effects.
Placeholder: these agents carry no antidepressant-induced switch signal.
Response timeline
Improvement builds gradually over several weeks.
Antidepressant Monotherapy Risk
An antidepressant given alone can destabilize bipolar mood.
- High: Switch Risk (AD alone) (placeholder metric)
- No: Stabilizer Present (placeholder flag)
- Class-wide: Guideline Warning (placeholder metric)
- Weeks 2–6: Onset of Risk (placeholder window)
Why monotherapy is risky
Unopposed antidepressant activity can push mood upward sharply.
Guideline stance
Major guidelines advise against AD monotherapy in bipolar disorder.
Placeholder: risk climbs the longer monotherapy continues.
Warning signs
Irritability and racing thoughts may signal early switch.
Switch-to-Mania Risk Visualization
The dial crosses euthymia and spikes into the manic zone.
- >80%: Peak Switch Risk (placeholder metric)
- Manic pole: Mood Overshoot (placeholder metric)
- Partial: Reversibility (placeholder metric)
- Elevated: Hospitalization Risk (placeholder metric)
The switch mechanism
Antidepressant drive overshoots mood past the stable zone.
Clinical consequence
A manic switch can require urgent dose adjustment.
Placeholder: switch risk scales sharply with treatment weeks.
Recognizing it early
Rapid mood elevation flags a treatment-emergent switch.
Safe Combination Strategy
A mood stabilizer shields against antidepressant-driven switch.
- AD + Stabilizer: Combination Approach (placeholder metric)
- Reduced: Switch Risk (combo) (placeholder metric)
- Quetiapine/Lamotrigine: Preferred Base Agents (placeholder metric)
- Weekly: Monitoring Interval (placeholder metric)
Combination rationale
Stabilizer coverage offsets antidepressant destabilization.
Practical protocol
Stabilizer is established before any antidepressant is added.
Placeholder: combination therapy keeps the dial near euthymia.
Long-term outlook
Maintenance therapy sustains mood stability over time.